Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “CHRS.”

Based in Redwood City, California, Coherus BioSciences, Inc. is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Hua Zhao and Dylan Service. Partner Rachel D. Kleinberg and associate Lena X. Qiu provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post